In line, our previous study has proved that lanifibranor (a pan-PPAR agonist) significantly improves liver steatosis and fibrosis in mice and in an in-vitro liver-on-a-chip model of MASLD 33. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.